211 related articles for article (PubMed ID: 37364599)
41. Cutaneous adult xanthogranuloma with a small portion of BRAF
Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
[TBL] [Abstract][Full Text] [Related]
42. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
[TBL] [Abstract][Full Text] [Related]
43. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
[TBL] [Abstract][Full Text] [Related]
44. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
[TBL] [Abstract][Full Text] [Related]
45. [Langerhans cell histiocytosis in adults].
Néel A; Artifoni M; Donadieu J; Lorillon G; Hamidou M; Tazi A
Rev Med Interne; 2015 Oct; 36(10):658-67. PubMed ID: 26150351
[TBL] [Abstract][Full Text] [Related]
46. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
47. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
48. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
[TBL] [Abstract][Full Text] [Related]
49. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
50. Clinical features and treatment of Langerhans cell histiocytosis.
Rodriguez-Galindo C
Acta Paediatr; 2021 Nov; 110(11):2892-2902. PubMed ID: 34192374
[TBL] [Abstract][Full Text] [Related]
51. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological features and BRAF
Huo Z; Lu T; Liang Z; Ping F; Shen J; Lu J; Ma W; Zhao D; Zhong D
Diagn Pathol; 2016 Oct; 11(1):100. PubMed ID: 27760550
[TBL] [Abstract][Full Text] [Related]
53. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
[TBL] [Abstract][Full Text] [Related]
54. Langerhans cell histiocytosis of the temporal bone: A review of 29 cases at a single center.
Modest MC; Garcia JJ; Arndt CS; Carlson ML
Laryngoscope; 2016 Aug; 126(8):1899-904. PubMed ID: 26535795
[TBL] [Abstract][Full Text] [Related]
55. [Elucidated pathogenesis and therapeutic prospects in Langerhans cell histiocytosis].
Morimoto A; Shioda Y; Sakamoto K; Kudo K; Imamura T; Kudo K
Rinsho Ketsueki; 2022; 63(5):373-382. PubMed ID: 35662160
[TBL] [Abstract][Full Text] [Related]
56. The Value of BRAF VE1 Immunoexpression in Pediatric Langerhans Cell Histiocytosis.
Phan DAT; Phung GB; Duong TT; Hoang AV; Ngo QD; Trinh DTN; Tran TT
Fetal Pediatr Pathol; 2022 Aug; 41(4):558-567. PubMed ID: 33295826
[No Abstract] [Full Text] [Related]
57. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
58. [Progress in the Treatment of Adult Langerhans Cell Histiocytosis --Review].
Tian ZZ; Cui YJ; Peng HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):970-974. PubMed ID: 35680836
[TBL] [Abstract][Full Text] [Related]
59. Pediatric Langerhans cell histiocytosis: state of the science and future directions.
Thacker NH; Abla O
Clin Adv Hematol Oncol; 2019 Feb; 17(2):122-131. PubMed ID: 30845115
[TBL] [Abstract][Full Text] [Related]
60. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.
Abla O
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):386-395. PubMed ID: 38066856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
